We are live on ! Find out more
BIOR

Biora Therapeutics, Inc. Common Stock

Delisted

BIOR was delisted on the 10th of December, 2024.

26 hedge funds and large institutions have $8.07M invested in Biora Therapeutics, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,433% more call options, than puts

Call options by funds: $166K | Put options by funds: $3K

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

4% less funds holding

Funds holding: 2726 (-1)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

39% less capital invested

Capital invested by funds: $13.3M → $8.07M (-$5.19M)

43% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 7

Holders
26
Holders Change
-1
Holders Change %
-3.7%
% of All Funds
0.38%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
5
Increased
4
Reduced
7
Closed
6
Calls
$166K
Puts
$3K
Net Calls
+$163K
Net Calls Change
-$319K
Name Holding Trade Value Shares
Change
Change in
Stake
HI
26
Harbour Investments
Wisconsin
$3
TAM
27
Tucker Asset Management
Colorado
$1
UBS Group
28
UBS Group
Switzerland
$1
BCM
29
Bridgeway Capital Management
Texas
-$29.2K -2,650 Closed
Jane Street
30
Jane Street
New York
-$19.6K -1,778 Closed
CIBC Asset Management
31
CIBC Asset Management
Ontario, Canada
-$16.6K -1,511 Closed
VF
32
Virtu Financial
New York
-$12K -1,101 Closed
Millennium Management
33
Millennium Management
New York
-$12K -1,089 Closed
Royal Bank of Canada
34
Royal Bank of Canada
Ontario, Canada
-$7 -1 -13%

BIOR Hedge Fund Activity: Q2 2024 in Review

26 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Biora Therapeutics, Inc. Common Stock (BIOR) for Q2 2024, worth a combined $8.07M — down 39% from $13.3M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of BIOR and 5 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 4 added.

The largest buyer was Vanguard Group, adding an estimated $82.5K. The largest seller was Bridgeway Capital Management, exiting entirely with an estimated $29.2K sold.

  • 26 institutional investors held Biora Therapeutics, Inc. Common Stock (BIOR) as of Q2 2024, down from 27 in Q1 2024.
  • Funds reported $8.07M of Biora Therapeutics, Inc. Common Stock stock for Q2 2024, down 39% quarter-over-quarter.
  • 5 funds opened new Biora Therapeutics, Inc. Common Stock positions in Q2 2024 and 6 closed out, a net change of -1 holder.
  • The largest Biora Therapeutics, Inc. Common Stock buyer in Q2 2024 was Vanguard Group, an estimated $82.5K added.
  • The largest Biora Therapeutics, Inc. Common Stock seller in Q2 2024 was Bridgeway Capital Management, an estimated $29.2K sold.

Based on aggregated 13F filings for Q2 2024.